Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin.
The authors prospectively studied the risk for immune-mediated heparin-induced thrombocytopenia (HIT) in neurologic patients during administration of low-molecular-weight heparin (LMWH) vs unfractionated heparin (UFH). None of 111 neurologic patients receiving LMWH developed HIT, whereas HIT occurred in 2.5% of 200 patients treated with UFH (p = 0.17). The rate of heparin-induced antibodies in patients treated with LMWH was lower than in patients treated with UFH (1.8 vs 20.5%; p < 0.001).
Pohl
C
C
Department of Neurology, University Hospital Bonn, Germany.
Kredteck
A
A
Bastians
B
B
Hanfland
P
P
Klockgether
T
T
Harbrecht
U
U
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology / Q000276:immunology*
D000925:Anticoagulants; D001323:Autoantibodies; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin